STMC-103H is under clinical development by Siolta Therapeutics and currently in Phase II for Allergies. According to GlobalData, Phase II drugs for Allergies have a 52% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how STMC-103H’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

STMC-103H overview

STMC-103H is under development for the treatment and prevention of atopic immunoglobulin E-mediated allergic disorder, allergic asthma, food allergy, atopic dermatitis, allergic rhinitis and other allergic diseases. It is a live bacteria containing consortia of intestinal bacteria and is administered through oral route.

Siolta Therapeutics overview

Siolta Therapeutics, is a developer of human microbiome therapeutics intended to prevent and treat inflammatory diseases. The company is headquartered in United States.

For a complete picture of STMC-103H’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.